Clinical Trials Directory

Trials / Unknown

UnknownNCT04336696

Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
199 (estimated)
Sponsor
Bassem Mohamed Sieda · Other Government
Sex
All
Age
42 Years – 55 Years
Healthy volunteers
Accepted

Summary

study assigned into three groups, Group I was the control group operated by total thyroidectomy and retrospectively followed, where the other two groups Operated by Total thyroidectomy and central neck dissection. Recurrence Free Survival (RFS) was the main issue of the study and calculated as the time from date of surgery to date of relapse or the most recent follow-up contact that patient was known as relapse-free, Study exclusively studied the outcome and advantage of central neck dissection

Detailed description

informed consent taken, study was a prospective cohort study, with controlled group a retrospectively. patients ablated by total thyroidectomy only who failed to achieve ablation with the first dose of iodine 131I may be dynamically risk stratified as high-risk category and managed aggressively. N0 patients will benefit and ablated by total thyroidectomy and prophylactic central neck dissection, PCND decreases the residual, increase the RFS and patients without residual do not need adjuvant RAI therapy except in high risk group. Histological grading, size of the primary tumour, the extension of PTC, the extent of surgery were found to be a strong predicting factor for recurrence-free survival Locoregional recurrence cases always found more in male patients aged more than 45 years old. Size of the primary tumour and the extent of surgery was a significant factor for RFS,

Conditions

Interventions

TypeNameDescription
PROCEDURETotal thyroidectomy and central neck dissection

Timeline

Start date
2016-11-02
Primary completion
2020-04-03
Completion
2020-05-03
First posted
2020-04-07
Last updated
2020-04-07

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04336696. Inclusion in this directory is not an endorsement.